Prior to this, published descriptions of what is now thought to be ORS appear from the late 1800s, with the first being Potts 1891. Often the condition was incorrectly described as other conditions, e.g. schizophrenia. Society
In modern times, commercial advertising pressures have altered the publics attitude towards problems such as halitosis, which have taken on greater negative psychosocial sequelae as a result. For example, in the United States, a poll reported that 55–75 million citizens consider bad breath a "principal concern" during social encounters. Etymology
The term olfactory reference syndrome comes from:

Olfactory, pertaining to the sense of smell. Reference, because of the belief that the behavior of others is referential to a supposed odor. Syndrome, because it is a recognizable set of features that occur together. See also
Fish Odor syndrome
Bad breath
Schizophrenia
Delusional disorder
Bipolar disorder

References
  
Dunne, T.P. (2015). "EMDR: An Effective and Less Stigmatising Treatment for Olfactory Reference Syndrome", EMDR Now, Vol. 7, No.1, Jan, pp 6–7.
All children, according to the U.S. vaccination schedule, should receive four doses, at two months, four months, six months, and again between one year and fifteen months of age.The CDC updated the pneumococcal vaccine guidelines for adults 65 years of age or older in 2019.In October 2021, the CDC recommended that adults 65 years of age or older who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown should receive a pneumococcal conjugate vaccine (either PCV20 or PCV15). If PCV15 is used, this should be followed by a dose of PPSV23. The CDC recommended that adults aged 19 to 64 years with certain underlying medical conditions or other risk factors who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown should receive a pneumococcal conjugate vaccine (either PCV20 or PCV15). If PCV15 is used, this should be followed by a dose of PPSV23. Efficacy
Prevnar-7 is designed to stop seven of about ninety pneumococcal serotypes which have the potential to cause invasive pneumococcal disease (IPD). In 2010, a 13-valent vaccine was introduced. Each year, IPD kills approximately one million children worldwide. Since approval, Prevnars efficacy in preventing IPD has been documented by a number of epidemiologic studies. There is evidence that other people in the same household as a vaccinee also become relatively protected.